Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study

Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotypes 1 and 6: real-world experience in Vietnam

(2018) Pham Thi Thu Thuy et al.   ANTIVIRAL THERAPY

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

(2018) Tarik Asselah et al.   Clinical Gastroenterology and Hepatology

Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout

(2018) Annsa C. Huang et al.   HEPATOLOGY

EASL Recommendations on Treatment of Hepatitis C 2018

(2018) Jean-Michel Pawlotsky et al.   JOURNAL OF HEPATOLOGY

Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens

(2018) Maissa El-Raziky et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan

(2018) Z. M. Younossi et al.   JOURNAL OF VIRAL HEPATITIS

Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis

(2017) Sabela Lens et al.   GASTROENTEROLOGY

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

(2017) Paul Y. Kwo et al.   JOURNAL OF HEPATOLOGY

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression

(2017) Reem Waziry et al.   JOURNAL OF HEPATOLOGY

EASL Recommendations on Treatment of Hepatitis C 2016

(2017)   JOURNAL OF HEPATOLOGY

Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience

(2017) N. K. T. Hlaing et al.   JOURNAL OF VIRAL HEPATITIS

Hepatitis C virus genotypes and subtypes circulating in Mainland China

(2017) Ying Chen et al.   Emerging Microbes & Infections

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial

(2016) Edward J. Gane et al.   GASTROENTEROLOGY

APASL consensus statements and recommendation on treatment of hepatitis C

(2016) Masao Omata et al.   Hepatology International

Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension

(2016) Mattias Mandorfer et al.   JOURNAL OF HEPATOLOGY

Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index

(2016) Jacqueline A. Bachofner et al.   LIVER INTERNATIONAL

Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection

(2015) Edward J. Gane et al.   GASTROENTEROLOGY

Current Treatment Options in Patients with Hepatitis C Virus Genotype 6

(2015) Nghia H. Nguyen et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis

(2015)   JOURNAL OF HEPATOLOGY

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

(2015) Jordan J. Feld et al.   NEW ENGLAND JOURNAL OF MEDICINE

24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial

(2015) Qingxian Cai et al.   PLoS One

Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model

(2014) Hamish Innes et al.   JOURNAL OF HEPATOLOGY

Hepatitis C virus genotype 6: Virology, epidemiology, genetic variation and clinical implication

(2014) Vo Duy Thong   WORLD JOURNAL OF GASTROENTEROLOGY

A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C

(2012) Pham Thi Thu Thuy et al.   JOURNAL OF HEPATOLOGY

Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More

(2011) B. L. Pearlman et al.   CLINICAL INFECTIOUS DISEASES

Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus

(2010) Michael J. Sofia et al.   JOURNAL OF MEDICINAL CHEMISTRY